Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

April 27, 2020

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 73 min

Earnings Call Speaker Segments

Speaker

unknown
#1

Good day, everyone, and thanks for holding. I'd like to welcome you to the Bayer investor and analyst call covering our first quarter 2020 results. During the recorded portion of today's session, everyone will be in listen-only mode. After the presentation, there will be a question and answer session. Should anyone have trouble hearing the conference, just press the star key and then zero on your phone, and an operator will assist you. At this point, I'll hand the conference over to Mr. Oliver Maier, who leads Investor Relations at Bayer AG. Please go ahead.

Speaker

unknown
#2

Alright, thanks a lot. Good afternoon, everyone, and thank you for being with us on this call covering the first quarter of 2020 results. Joining me are Werner Baumann, who is our CEO, and Wolfgang Nickl, our CFO. The individual businesses are represented here by the management board members who bear responsibility for them, and those colleagues are also on the line. Representing Pharma is Stefan Oelrich. For Consumer Health, Heiko Schipper is with us. Liam Condon represents Crop Science. Werner is going to open today's call by walking through our priorities given the pandemic crisis, then our group's financial performance, and how the divisions performed. After that, Wolfgang will take you through the first quarter financials, the outlook, and the areas we are focused on most, and then we'll begin the Q&A session. As I always do, let me begin by pointing you to the cautionary language contained in our safe harbor statement, and also in all of the materials we have distributed today. With that said, Werner, over to you.

Speaker

unknown
#3

Okay. Thank you, Oliver. Good afternoon, everyone. I'm glad to have you join this conference call. I'll begin with the issue that's clearly foremost on everyone's mind. This pandemic is unlike anything we've seen, and it touches every one of us, in our personal lives and at work. Our vision — "Health for all and hunger for none" — has never mattered more. We know our deep know-how in health and nutrition gives us a distinctive chance and duty, and we've answered with medical help as well as financial help for those hit hardest. Right now we're assessing whether Resochin, our malaria drug that's over 80 years old, could treat people suffering from COVID-19, and we've donated a substantial number of tablets in various countries. We're also helping in the hunt for a new active substance against COVID-19 as part of the Innovative Medicines Initiative, and we've given money to badly affected regions in China, Italy, and Spain. On top of that, we supplied medical equipment such as face masks and disinfectant liquids, and we've managed to greatly expand PCR testing capacity in Germany by providing testing capacities at no charge. Over 140 of our colleagues in Berlin volunteer their time to produce these tests.

Speaker

unknown
#4

In addition to those humanitarian actions, our attention is on protecting the health and safety of our employees, and to us that matters more than anything. Strict health and safety protocols have been put in place at every site. On top of that, we have required people to work from home wherever that is feasible. Our IT team is performing remarkably well, keeping our IT infrastructure operational even with volume increases that are unprecedented. At present we are handling as many as 140,000 video calls or conferences each day. As a global leader in health and nutrition, we also carry a tremendous responsibility toward the patients, consumers, and growers who depend on getting access to the products they need. Serving them well through an uninterrupted supply of our medicines and agriculture products is foremost in our minds. We take great pride in all of our employees, who are motivated by the purpose and the vision of our company, and in witnessing every single day the difference their work makes. Before we move on, I want to offer a few remarks about the glyphosate litigation, which the crisis has also affected. The trial schedule is still fluid and subject to change, and as of now no new trials are set to start before the end of June 2020.

Speaker

unknown
#5

But the California Court of Appeals is still proceeding with its process, and it has set the hearing in the Johnson trial for June 2nd, with a decision expected by August 31st. Along a parallel track, we've made headway in the Roundup mediation talks, though COVID-19 dynamics and the restrictions tied to them have slowed that progress considerably, and we expect that to remain the situation in the near term. We can't speculate on what the negotiations might yield, but we stay committed to taking part in mediation in good faith, and we'd consider a solution only if it is financially reasonable and establishes a mechanism for resolving potential future claims efficiently. With a looming recession in the background, and in some cases given the liquidity challenges, that applies now more than ever. Let me also update you on the capital markets day we had planned for the end of June. Given the ongoing pandemic, the associated health risks and that continuing uncertainty, it's unlikely we can host the capital markets day with you there in person. So we've decided to postpone the event until later this year. In the meantime, we're focused on safeguarding our employees and, of course, on business continuity to serve farmers, patients and consumers who are in dire need of our products.

Speaker

unknown
#6

Against that background, I'd like to give you an update now on how the group and our divisions performed in the first quarter. We saw sales climb past EUR 12.8 billion, an improvement of 6% after adjusting for currency and portfolio effects, and EBITDA before special items was up 10%, at EUR 4.4 billion. Core EPS came in at EUR 2.67, an increase of nearly 10% from the prior year. Free cash flow is at minus EUR 793 million, versus roughly a positive EUR 500 million in Q1 of last year. That decline was anticipated and is not a consequence of the pandemic crisis. It stems from the working capital phasing we expected, along with expected special effects that Wolfgang will cover shortly. Let me finish with a word on our outlook. As a reminder, the full year guidance we gave in February contained no financial impact from the coronavirus outbreak. Since that time, the virus has quickly grown into a pandemic, and how it affects us over the coming months will be determined by its duration and intensity. In light of these unprecedented dynamics, we are not yet in a position to reliably quantify the effects. Certain of them are negative, and certain are positive. Wolfgang will walk you through the variables whose potential impact on our business we are continuously assessing.

Speaker

unknown
#7

We’ll provide a further update later in the year. Now I’ll move on to how each of our divisions performed, beginning with Crop Science. In the northern hemisphere, farmers are starting to plant, while harvest is already taking place in the southern hemisphere, and Crop Science has made a solid start in 2020. Sales rose 6% on a currency- and portfolio-adjusted basis, with increases in every region, mainly led by EMEA and Latin America. In Latin America, sales were strong in corn, soybeans, and fungicides as Intacta Roundup Ready 2 Pro acre penetration rose by almost 9% for the season, and Fox Xpro fungicide kept expanding in Brazil. EMEA’s growth was driven by corn, fungicide, and insecticide sales, supported by an early start to the season in Central Europe and an anticipated rebound from dry weather across the region. In North America, we still expect 10 million to 12 million more planted acres of corn and soybeans in the U.S. We recorded solid growth in corn seed and traits, herbicides, insecticides, and cotton seeds and traits. That was partly offset by lower soybean seed and traits, where the competitive pressure seen last year remains. On earnings, Crop Science lifted EBITDA before special items by 14% to EUR 2.6 billion.

Speaker

unknown
#8

The main forces behind this gain were higher volumes along with ongoing cost synergies stemming from integrating the business we acquired. We are still on course to deliver over 70% of the synergies we target for Crop Science by the close of 2020, and to hit total targeted cost synergies of roughly EUR 870 million by 2022. Now let's turn to Pharma. First-quarter pharmaceutical sales climbed almost 4% on a currency- and portfolio-adjusted basis, reaching EUR 4.5 billion. Xarelto, our top-selling product, kept up its solid performance. It rose 19% overall, led by EMEA, partly because order patterns shifted in connection with COVID-19. Eylea posted just a modest 1% gain in the first quarter. Increases in the U.K., Germany, and Canada were partly offset by decreases in Japan, France, and Italy. Japan's movement reflected phasing, while France and Italy were mainly hit by reductions to price lists. China saw a sales decline, chiefly from the anticipated lower pricing tied to volume-based procurement effects for both Glucobay and Avalox, which are expected to take effect on April 1. Keep in mind that the government has begun launching the next round of volume-based procurement with a slight delay — in mid-April, in fact. Thanks to that sales growth, our EBITDA before special items for pharma was up 7%, at EUR 1.6 billion.

Speaker

unknown
#9

We also had some encouraging product news to share. Beginning with Nubeqa, we got approval in the European Union for darolutamide as a new therapy for men who have non-metastatic castration-resistant prostate cancer. Nubeqa has a chemical structure that works to inhibit prostate cancer cell growth while reducing certain side effects for patients fighting the disease. Also, only weeks ago, the European Medicines Agency approved the Eylea prefilled syringe, giving ophthalmologists a more efficient and convenient option for using Eylea. Compared with the existing vial, the prefilled syringe takes fewer steps to prepare injections, so that's great news for one of our most important pharma offerings. Now turning to Consumer Health to wrap up the divisional updates. That division posted sales growth of 14%, fueled by a substantial rise in demand tied to the COVID-19 pandemic, partly from inventory buildup. Thanks to our supply chain operation, we responded very flexibly to significantly higher volumes and to shifts in the product mix. Most notably, nutritionals and multivitamins in Asia Pacific and Latin America were our biggest growth contributors. Overall, demand was strong across all regions, though a bit softer in China, given the effect of the lockdown during the peak of the coronavirus infections and some supply disruption related to COVID-19.

Speaker

unknown
#10

Turning to earnings, higher volumes lifted EBITDA before special items, even though we no longer have contributions from the businesses we divested. On top of that, our Fit-to-Win growth acceleration program is delivering positive results. With that, I'll hand it over to you, Wolfgang, to go deeper on our financial results and outlook.

Speaker

unknown
#11

Thanks, Werner. And hello everyone, a warm welcome from my side as well. Now I'll take you through a few more financial specifics for Q1, and after that I'll discuss the key impact variables and areas of focus for the rest of the year. Let's begin with Q1. Currency- and portfolio-adjusted sales rose 6% to EUR 12.8 billion. EBITDA before special items reached EUR 4.4 billion, 10% higher year-on-year, supported by sales volume growth in every division and continued efficiency improvements. Our group EBITDA margin was up 170 basis points at 34.2%. Foreign exchange effects gave a positive year-on-year impact of EUR 44 million on sales and a positive impact of EUR 41 million on EBITDA. Although the first quarter saw a positive impact, for the full year we currently anticipate material negative effects, driven by the Brazilian real, Russian ruble, and Mexican peso, given their recent devaluations. Core earnings per share rose 10% year-on-year to EUR 2.67. The core financial result moved from minus EUR 352 million to minus EUR 493 million, mainly relating to currency losses, including hedging costs and the change in the fair value of debt instruments. Our core tax rate for the quarter came in at 24.4%.

Speaker

unknown
#12

For the whole year, we still anticipate it being approximately 23%, consistent with our guidance. Lastly, free cash flow for the quarter declined versus the previous year, moving from EUR 508 million to negative EUR 793 million. That impact fell inside what we had anticipated. The drop isn't caused by the pandemic crisis; instead, it stems from working capital phasing and special effects. Within Crop Science, comparatively early collections and prepayments at the close of last year, along with lower payables, produced this phasing effect. In addition, we made the payment we expected for the Xarelto settlement and began moving U.S. incentive payments from the second quarter into the first quarter. It goes without saying that protecting liquidity in these unusual operating conditions matters enormously to us. Next, let's go through the bridge from core EPS to reported EPS for continued and discontinued operations. On the left-hand side of this chart, we begin with EUR 2.67 core EPS for continued operations in the first quarter. The following column, showing an adjustment of minus EUR 0.86 per share, consists mainly of acquisition-related amortization of intangibles and PPE. It contains a write-up on the Consumer Health brand Afrin and an anticipated additional impairment tied to a herbicide plant.

Speaker

unknown
#13

Special items affecting EBITDA came in at a negative EUR 0.63, driven mostly by costs for restructuring, integration, and litigation. That litigation figure includes a provision tied to continuing legal efforts on Essure. The special items sitting in the financial result are largely tied to fair value movements on our Covestro shares. The following column shows the offsetting tax effects on the sum of the items I just walked through, which brings us to EPS from continuing operations of EUR 1.39. Then there's a strong contribution of EUR 0.13 from discontinued operations — the Animal Health business — which takes EPS from continued and discontinued operations to EUR 1.52 for the first quarter of 2020. Let's turn now to the balance sheet. Net financial debt rose slightly, by EUR 1.3 billion versus the end of last year, primarily because of the negative free cash flow I discussed earlier along with the U.S. dollar's appreciation during the quarter. As a reminder, almost 60% of our financial debt is denominated in U.S. dollars. So for each percentage point the U.S. dollar appreciates against the euro, our net financial debt goes up by roughly EUR 200 million, and the reverse holds as well. As Werner said at the start, the pandemic is a situation that keeps evolving.

Speaker

unknown
#14

Although we can't reliably put a number on COVID-19's impact at this point, I can walk you through the key variables we're tracking. Safeguarding supply of critical medicines and agricultural products for our patients, growers, and consumers is our priority. Every one of our production sites is running right now, and so far we've seen only limited supply chain disruptions. But this is clearly a challenge, particularly given that shipments of active ingredients and APIs from countries such as India could be hampered. It also means we're watching and managing safety stock levels closely to offset possible logistics delays or raw material shortages down the road. Beyond that, we're rethinking logistics, and we recognize that logistics costs have risen substantially in many cases. Meanwhile, we're keeping a close eye on our customers' credit situation and payment behavior, and on our suppliers' liquidity. We're watching the debt markets and have taken the appropriate steps to secure our own liquidity in an environment where, for instance, the commercial paper market is significantly limited. Credit spreads have widened, as have new issue premia, and that could push our funding costs higher going forward.

Speaker

unknown
#15

As we said earlier, the crisis caused a major shift in currency markets, and at today’s rates that will take a substantial negative toll on our results. Beyond that, we’re watching demand trends affecting the business. First, changing demand patterns could lower demand for certain pharma products—for example, Eylea or Mirena, if patients can’t get to the doctor for refills or elective procedures. Second, in Consumer Health, we saw a first-quarter surge in demand for some products, which involved stockpiling as well as higher consumption, especially in nutritionals. Finally, in Crop Science, shifts in demand for biofuel and key grains could alter the acres planted in our focus crops, which would affect expected sales and production plans in future years. Within pharma, we might see some delays for products in development because of reduced enrollment or participation in our clinical trials. In addition, delays in regulatory processes are possible across our businesses as governments juggle different priorities while the situation unfolds. To offset some of the negative effects, we are actively managing our flexible spend. Given movement and meeting restrictions, we would expect, for instance, lower travel and event costs.

Speaker

unknown
#16

We also need to assess how project costs will be affected, based on how long the crisis lasts and possible shifts in project priorities. Beyond that, recent weeks have shown us just how much can be accomplished digitally, and we'll work to keep the positive aspects and speed up our digital agenda. Lastly, we've also seen lately that science's role in society has been raised, which we at an innovation company view as a very favorable development. To be clear, we got off to a solid start in 2020 with the first quarter, and we're keeping our operational targets for the year. That said, we'll have to respond to the dynamics I've just outlined. We're hoping for a clearer line of sight to quantify the positive and negative impact variables, and we'll give you revised guidance as soon as we can. Let me finish with our focus areas for the year. I've just shared our intentions for our operational targets, with particular emphasis on cash flows throughout the group. Next, we'll carry on with our post-merger integration processes, along with our ongoing emphasis on pipeline execution in Crop Science, after a year of meaningful progress in 2019. In the same way, we expect to keep advancing our pipeline and new product launch plans in Pharma, including for products such as Nubeqa, Vitrakvi, vericiguat, and finerenone.

Speaker

unknown
#17

When it comes to Consumer Health, we're still pushing ahead with the initiative meant to speed up our growth. And lastly, we're carrying on with delivering on the Bayer 2022 programs aimed at boosting efficiency, and we anticipate the Animal Health divestiture will close around mid-2020. I appreciate everyone spending time with us today, and we're eager to update you routinely on how things are going in these priority areas. So with that said, Oliver, I'll turn the call back to you so we can get the Q&A started. Excellent. Thanks, Wolfgang. And thank you, Werner, for that summary.

Speaker

unknown
#18

Before we start, I'd ask everyone to limit themselves to roughly 2 questions each, since the queue is quite long — that way we can get to as many participants as possible within the time we have. Haley, I believe we're ready to open the lines for questions now.

Speaker

unknown
#19

Thank you. Ladies and gentlemen, we're going to start the question-and-answer portion at this point. Should you wish to ask something, kindly press the star key and then the one on your phone. To withdraw your request, press the star key followed by the two. Questions will be taken in the sequence in which they arrive. If you're on speaker equipment today, please pick up the handset before you make your selections. Please hold a moment for the first question. Our first question is from Mr. Andrews. Kindly give your name, the name of your company, and then your question.

Speaker

unknown
#20

Thank you. This is Vincent Andrews with Morgan Stanley. Liam, could you walk us through how you hedge the ag business, especially exposure to the Brazilian real, which has clearly moved dramatically? And I'd also like your thoughts on what you're able to do on pricing in the second half. Specifically, I'm thinking about Intacta, where I understand the contract includes certain pricing restrictions, and also what's possible on the seed side compared with what you can accomplish in crop chemistry. Are there differences in pricing power between those two? Thanks.

Speaker

unknown
#21

Alright. Wolfgang, would you like to begin with hedging? I can give a general overview of hedging. Then we'll go to Liam. I'll share a few high-level points about hedging, and then Liam can address the Brazilian real specifically. As I mentioned, we witnessed considerable devaluations in major currencies including the Brazilian real that you brought up, as well as the Mexican peso and the Russian ruble near the end of the year. Since we hedge more heavily early in the year compared with later, and our business in the Southern Hemisphere is greater in the second half than in the first, that effect meant Q1 was in fact positive, though we regard it as negative for the rest of the year. As a reminder, we hedge transaction exposure by hedging the full booked exposure and roughly 50% of the forecasted exposure. That's the same approach we've used previously. Translation exposure is not hedged by us. Given high volatility, we always provide guidance at constant currencies, and we'll keep updating you through the year on how this evolves. Once again, Brazil matters a great deal to us.

Speaker

unknown
#22

Back in 2019, that country ranked second in revenue for the year. With that said, Liam, I'll hand things over to you for the specifics on Brazil.

Speaker

unknown
#23

Thank you, Wolfgang. And Vincent, I appreciate the question. Fortunately, we've had a presence in Brazil and across Latin America for a good while now, and sadly, sharp currency fluctuations are something we're accustomed to. Over time, we've come up with a range of different tools aimed at offsetting or reducing those risks to the greatest extent we can. Basically, our approach is to tie prices to the US dollar wherever feasible. A classic illustration is Crop Science in particular. The price is set in real and the invoice is issued in real, yet we essentially revise the price lists on an ongoing basis any time there's a meaningful shift in the currency markets. That's one central way we attempt to reduce risk. When it comes to Argentina, our functional currency there is in fact the US dollar, so in that case we sort of have a natural hedge inherent in the setup. We've grown a considerable share of our business around barter, giving us yet another extra hedge there. And then, as Wolfgang already mentioned, we have assorted financial hedging options wherever those are sensible. Broadly speaking, some level of exposure to major currency swings always exists in Latin America. Still, we have numerous mechanisms in place to try to reduce it to the greatest extent we can.

Speaker

unknown
#24

And to follow up on that, thinking about the Crop Science business outside of the countries where farmers export their crop after harvest and gain from that stronger US dollar — are you noticing any shifts in demand, whether from dealers, distributors, or farmers themselves, given that farmer economics have gotten a bit worse?

Speaker

unknown
#25

No, but honestly it's probably too early to tell at this point. I mean, we're wrapping up the LATAM season — the Brazilian season in particular — and up here in the northern hemisphere we're really just getting started. So frankly, I'd say it's simply too soon to make that call, and my hope is that in Q2 we'll be better placed at that time to give you a further update on it.

Speaker

unknown
#26

Much appreciated. A good beginning to the year.

Speaker

unknown
#27

I appreciate that.

Speaker

unknown
#28

Our following question is from Mr. Kapadia. Kindly give us your name and the company you represent, then go ahead with your question.

Speaker

unknown
#29

Thanks for taking my questions. This is name from Bernstein. If I could just begin with Eylea, please. Can you quantify how much of the weakness in 1Q was tied to price declines in Japan and France? How much was actually connected to COVID-19? I was just trying to get a sense of the impact you saw in the last few weeks of March and what you're seeing in early April. You previously guided to high single digit. Does that still hold, and should we expect a catch-up in 2H? My second question is on vericiguat. You recently presented the phase III data in reduced ejection fraction, where the headline risk reduction looked somewhat modest, but in certain populations, clearly you saw a much larger benefit. I guess, what kind of feedback have you had since the data was presented, and has that changed your thinking around where the product fits into the treatment paradigm? Here, I'm thinking SGLT2s as a threat. Do you still stand by the 0.5 billion peak sales guidance for the product? Thank you very much.

Speaker

unknown
#30

Yes. Hello, Emil. Appreciate the questions. Regarding Eylea, we have observed certain phasing tied to pricing in Italy, France, and Japan as well. That is the primary effect we have noticed across the first three months. With COVID, it is difficult to determine whether it already had an impact in March. There might be a bit of that in there, but it is hard to tell. So in the first quarter, what we mostly see is more of a phasing effect from pricing adjustments in those three markets. On vericiguat, we are receiving plenty of encouraging feedback after our data presentation. You are correct that, at first glance, the 10% relative risk reduction does not appear overwhelming. However, if you consider the absolute risk reduction of 4.2%, and if you examine the data closely and recognize that we were studying an extremely sick population, then this is a very strong result. As you look further into it — and you have likely seen the data — in the lower three quartiles of baseline NT-proBNP levels, we observe relative risk reduction reaching 27% in certain populations. We are hearing considerable positive feedback about that from the physicians we have spoken with following the ACC presentation, which was virtual this year.

Speaker

unknown
#31

Gathering the kind of feedback we'd typically get from in-person conversations at these meetings is genuinely difficult. Still, it's positive. There's no reason for us to alter our peak sales assumptions. We believe this remains a good fit. Where will it go? That question isn't so easy to answer, since we'll have to wait and see what the guidelines say, later this year or early next year. It's probably more next year that we're going to see this in the guidelines. What we've demonstrated so far is efficacy in a population that no one has studied the way we have. This is the most difficult to treat population that's out there. I think that says a great deal about the quality of vericiguat.

Speaker

unknown
#32

Thanks a lot. That's much appreciated.

Speaker

unknown
#33

Jo Walton has the next question. Kindly give your company name, then ask your question.

Speaker

unknown
#34

Thank you. This is Jo Walton with Credit Suisse. I'd like to stay on pharma and then move to consumer, please. I'm wondering whether you could help tease out for us what you believe the underlying growth rate was during the first quarter, stripping out the positives and negatives related to COVID-19. Regarding any wholesaler stocking included in that figure, over what time frame do you expect it to reverse? On the pharma side, could you also share a bit more detail about Nubeqa? In the U.S., we've recently seen a very nice uplift in prescriptions there. Is that because you've eased some reporting restrictions, so what we're seeing was already present but is now more evident to us? Or are you gaining significant share? If I could ask the same from a consumer standpoint, what do you feel the underlying performance was in the first quarter, and when might any stocking unwind? Thank you.

Speaker

unknown
#35

Jo, thanks. When it comes to underlying growth tied to COVID-19 versus non-COVID-19, it's genuinely difficult to separate the two. We're seeing some favorable impact on Xarelto in the first quarter. Whether that reflects inventory buildup or an actual effect, we'll have to wait and see. We're also hearing about an effect from more switching away from vitamin K antagonists, since going to a NOAC involves less patient monitoring. My expectation is that this will persist, but we'll have to see. Teasing those two apart is really hard. On hemophilia, we've also seen some good development. There may have been some inventory building there, but it's really hard to tease out. On the other side, we've had low volumes for Glucobay in China. So along the way, we've had some pluses and some minuses. Thank you for your question about Nubeqa, because you've been among the more critical voices on Nubeqa. So I'm glad that you're now seeing in the numbers some of what we had been telling you, which stems from the program we put in place for patients so they would have better access to our medication. We're very happy with how Nubeqa is developing.

Speaker

unknown
#36

In our first launch country, it is exceeding what we had anticipated by a wide margin so far. Approval in Europe has now come through, and that only adds to how excited we are. Germany will be the first European country where we introduce it. So things are moving in the right direction.

Speaker

unknown
#37

Alright. Thanks, Stefan. Heiko, would you like to add a few remarks about underlying demand in Consumer Health for Q1?

Speaker

unknown
#38

Yes. Thanks, Werner. Clearly, this is the big question everyone wants answered. We too are attempting to figure out what portion reflects additional inventory stocking versus what is genuinely consumption. We're tracking that very carefully alongside shoppers and retail partners. The reality is that it's simply too soon to tell. This isn't an effect spanning all of Q1. As all of you know, it ramped up dramatically in March. Essentially, we're only in month two of the true escalation of this crisis — the pandemic — particularly, of course, across Europe and in North America as well, where our biggest businesses sit. Just a few underlying points, without getting into specific figures, since we simply can't yet. Clearly, demand for supplements, for vitamins and minerals, is definitely higher too. I think we all know that from our own experience — we're taking more of them these days. We're also noticing that perhaps certain other categories, such as allergy or cough and cold, where people genuinely just want to steer clear of getting ill, because they don't want to wind up at the doctor or in the hospital, or they want to respond right away to the first cough they get. We are definitely seeing some gains there as well.

Speaker

unknown
#39

My sense is that after we've gotten past Q2, we ought to be in a position to develop a clearer view for ourselves, though right now it's genuinely too soon to give you any real breakdown of it.

Speaker

unknown
#40

All right, thank you, Heiko.

Speaker

unknown
#41

Emmanuel.

Speaker

unknown
#42

Mr. Papadakis has the next question. Kindly give us your name and your firm's name, and then ask your question.

Speaker

unknown
#43

Thank you. This is Emmanuel Papadakis from Barclays. I'll do my best to keep it to just a couple of questions. First, perhaps regarding that additional data set that was shown at ACC: Stefan, could you share your views on what VOYAGER might imply, and whether it would do anything to tackle the rather lukewarm medical reception that COMPASS received when it comes to broadening Xarelto's use? Then, for the second question, on the ag side — this one's for Liam — if you could just expand on how you see things regarding the possible effect on the corn outlook should the collapse in bioethanol demand in the U.S. continue for any stretch of time. Maybe you'd like to put a number on how long you think it would take before that essentially turns into a meaningful negative impact, especially as we look toward 2021. Many thanks.

Speaker

unknown
#44

Alright, thanks, Emmanuel. Stefan, you’ll go first, and then Liam will handle the second one.

Speaker

unknown
#45

Hi, Emmanuel. Regarding VOYAGER, yes, certainly, we're pleased that there's another study with positive results following so many positive trials involving Xarelto. A 15% relative risk reduction on the primary endpoint is genuinely strong. What pleases us about this trial is our belief that the PAD patient can be somewhat more easily identified by a physician than perhaps the CAD patient can. Thus, we think this will assist us in making the advantages of this new dosing even clearer for patients. So that ought to provide a boost and help pinpoint the appropriate patient groups for key prescribers. Yes, we're confident that this will help drive an increase. We concur that up to now, CAD PAD hasn't truly been as exciting as we'd have liked.

Speaker

unknown
#46

Liam.

Speaker

unknown
#47

Alright, thank you, Emmanuel, for that question. I believe this is a very significant question, and it's quite hard to answer with certainty at this point — namely, what effect the drop in biofuel demand and ethanol will have on corn demand moving forward. Our view is that the effect during this season in the Northern Hemisphere will likely be quite limited. In our assessment, most growers have likely already finalized their growing decision, their planting decisions. If anything, it would more likely be a matter for the next growing season in the Northern Hemisphere. So perhaps toward the end of this year or as we move into 2021, we could see an effect. We have been attempting to put numbers on this. USDA has been projecting corn acres for this season at roughly 97 million acres. Considering that 30% of ethanol demand originates from corn, and translating that into acres while looking at some of the various estimates that exist, the effect on acreage could range anywhere from 2 to 5 or 6 million acres. The question is whether this will actually materialize. We simply don't know. There are plenty of insurance and assistance governmental programs available to support growers at present. What we're also observing are anecdotal reports regarding higher demand from China and a possibility that China could raise its imports of corn, something they haven't really done over the last few years.

Speaker

unknown
#48

People are mentioning that China might buy roughly 20 million tons of extra corn. That would work out to somewhere around 4 or 5 million acres of corn too. So there's plenty of back and forth. It's simply too soon to say how this will play out, but once again, we wouldn't truly anticipate the effect landing in this growing season — if there is going to be one, it's likely in the following growing season instead. Beyond that, ethanol demand will hinge on the sort of stockpiling China does for the next season as well.

Speaker

unknown
#49

Thanks, Liam and Stefan.

Speaker

unknown
#50

Our following question is from Mr. Vosser. Kindly give us your name and the firm you represent, then go ahead with what you'd like to ask.

Speaker

unknown
#51

Hi, thank you for taking my question. A couple of things, please. First, regarding volume-based procurement in China. Obviously, there is some impact from your pricing, but could you perhaps give us a sense of how you expect volume demand to recover in Q2, 3, and 4? We are seeing other companies achieve substantial volume increases thanks to the price reductions they have made, which is offsetting part of the impact. Just your thinking on that for Avalox and Glucobay. Next question, going back to Crop Science, please. Maybe you could give us a sense of the future soybean demand you are seeing. Both volume and price, how should we think about that in the second quarter and perhaps into the Latin American season in the second half as well. Thanks very much.

Speaker

unknown
#52

Richard, Stefan will begin.

Speaker

unknown
#53

Hi Richard. Yeah, my apologies. Honestly, I don’t have particularly solid guidance for you on that. I wish I had precise knowledge of it. I’ve also observed other competitors experiencing some volume response after their VBP wins. Some portion of that would likely be anticipated, but at this point I’m unable to quantify it.

Speaker

unknown
#54

All right, thank you, Stefan. What about demand for soybeans going forward?

Speaker

unknown
#55

Okay, thanks, Richard. As with every topic, the outlook at this moment is quite hard to call. Let me attempt to offer a few guideposts on how we're viewing it. Naturally, in the U.S. right now, we're still in very early days, so essentially no planting has happened yet. At this point it's purely a matter of guessing how things will unfold. What we initially projected assumed what we term a return to normal weather, meaning we'd see another 5 million-7 million acres of soybeans planted this year in the northern hemisphere. At the outset we were also projecting an extra 3 million-5 million acres of corn, and we're still hopeful that materializes. How it actually shakes out truly hinges now on weather and trade. As you'll recall, at this same point last year, we were making particular calls, and then conditions deteriorated sharply later in Q2. Heavy rains were already present at this time last year, but afterward the soybean planting season was essentially wiped out. It's very early to make the call right now, but under normal circumstances we would expect 5 million-7 million additional acres. On our side, we are counting on still having roughly 50 million acres of the Xtend system within this year.

Speaker

unknown
#56

We've actually built in some market share loss for this year, along with a price decrease in the low single digits for Xtend. The reason is straightforward: Enlist is a brand-new competing system that just hit the market, and it will capture some share since its yield performance isn't as strong. Pricing out there is very aggressive. Going to that kind of cutthroat level makes no sense for us, since all we'd do is devalue the markets. We have to accept some market share decline, and we're willing to do so, because we're coming out with a new system afterward, XtendFlex, which we hope to get approved later this spring, with a small commercial launch this year and then a full commercial launch in 2021. That's broadly how we're looking at soybeans overall, especially in the northern hemisphere. In LATAM right now, where before COVID-19 we were essentially predicting flat soybean acreage, I wouldn't offer any further forecasts on that at the moment. We simply need to see how things develop.

Speaker

unknown
#57

Alright, thank you, Liam.

Speaker

unknown
#58

We now move to a question from Florent Cespedes. Kindly give your company name first, then ask your question.

Speaker

unknown
#59

Good afternoon, this is Florent Cespedes at Société Générale. I have a couple of questions for Stefan. To start, regarding clinical trials and the possible effect of COVID-19, could you say a bit more about which trials are most likely to be affected and possibly delayed? Might we see some delay in the phase III programs, particularly in ophthalmology, perhaps? My second question is also for Stefan. On marketing campaigns, do you anticipate any negative effect from the present situation on your campaigns across the portfolio, and which products are most likely to come in a bit softer because the marketing campaigns are having less impact? Thank you.

Speaker

unknown
#60

Hello, Florent. On the clinical trial front, I'm glad to say that things are actually going fairly well for us at the moment. We've basically completed the clinical trial on FIDELIO. That's our big pivotal phase III study for finerenone. It's an important one for us. Overall, for the trials we're reporting on this year, we're actually in pretty good shape. We might see some delays in getting new ones started early on. Yesterday I saw information that the FDA is now pretty much overwhelmed with COVID-19 applications — luckily we have one of them, also for a phase II product, which will go into the ARDS indication, which we're advancing, and we're seeing record-fast responses from the FDA. We hope to be able to help COVID-19 patients with that. Overall, we're actually doing quite well. Obviously, my biggest concern was whether we could get the FIDELIO trial in, but it looks like we've completed it. On the marketing campaigns, this is a really good one. We've seen record-fast adoption of digital by our troops. We've made a leap, as I think anyone has, in 4 weeks that would normally take us probably 4 years.

Speaker

unknown
#61

Fortunately, we already had a genuinely robust infrastructure built on Veeva, and adoption of it is now proving remarkable. As for the impact and whether it might help or hurt us, only time will tell. During Q1, I don't believe there's been any effect as of yet, and we'll need to keep watching going forward, since you're correct that at present it's hard to meet customers in person outside of video conferencing. Even in that setting, though, I have to say our platform enables us to conduct those kinds of customer interactions, and customers respond very well to them — perhaps even better than we'd anticipated. I suppose that's true for everybody at the moment.

Speaker

unknown
#62

Okay, thanks a lot, Stefan.

Speaker

unknown
#63

Our following question is from Mr. Verdult. Kindly give us your name and the company you represent, then ask your question. Mr. Verdult, go ahead and unmute your cellphone.

Speaker

unknown
#64

Okay, sorry about that. Good afternoon — this is Peter Verdult from Citi. I’ve just got two questions for Wolfgang, please: one on cash and one on synergies. Thanks for walking through the free cash flow in Q1, but I wanted to clarify two figures: is the free cash flow guidance for 2020 still $5 billion? And am I correct that the net proceeds from the divestments you hope to complete in the middle of the year come to just over $8 billion? Then, on synergies: some of your European pharma peers, who are also going through restructuring, are strongly hinting — with the COVID-19 crisis in mind — at areas where they can drive further efficiencies. I’m wondering whether you could go into that in a bit more detail, in terms of what further opportunities you have to push your synergy program forward and where you stand on considering deliveries. Thank you.

Speaker

unknown
#65

Alright, Pete — thanks for those questions. I’ll begin with free cash flow. Just to confirm again: yes, it came in significantly below the prior year, but it was essentially in line with what we had expected for Q1. As you may remember, last year we guided to $3 billion-$4 billion through the middle of the last quarter. We had anticipated landing in the middle of that range, yet we ended at $4.2 billion, so there were fairly notable phasing effects running into Q4 and Q1, and those were amplified by certain special charges, such as the Xarelto settlement. I also noted on the call that we pulled some payments forward into Q1 that otherwise would have occurred in early April. On free cash flow guidance, our target is $5 billion. By the way, if you have read the invitation to the AGM, free cash flow is now also part of our board of management incentive system. But you will understand that all the vectors, or most of the vectors, that we laid out during the call and during the Q&A may also affect free cash flow for the year. So we will provide an update on that as we go. Obviously, free cash flow in the guidance was also pre-potential settlement, should one come in.

Speaker

unknown
#66

Regarding the $8.4 billion in net proceeds, I want to remind everyone of two points. To start with, Coppertone, Dr. Scholl's, DermaRx, and Currenta were all already completed during 2019. As a result, no new cash is coming from those. Beyond that, that money was never included in free cash flow in any case. So what will arrive in 2020, once the deal closes, is the proceeds from Animal Health. And as you know, 70% of that is the cash portion. Judging by the statements we hear from Elanco, we feel quite confident this could close by the middle of the year. I believe you've seen that they filed the appropriate Form CO with the EU, and we are now moving into those proceedings. So that looks rather positive. The remaining 30% then gets paid to us in Elanco shares, and those are subject to a collar. There is, however, some risk and opportunity tied to the Elanco share price. Naturally, we have the choice of when to sell them. That would depend, so the cash portion, of course, would come in this year. Parts of the share sale could come in this year, but most likely not the whole effort. On synergies and efficiency programs, I think, Werner, you had it in your prepared remarks, we are actually doing really well, not only on the synergy program for post-merger integration, but also across all the efficiency programs.

Speaker

unknown
#67

Back in 2019, we hit 30%. Now our target for 2020 is 50%, then 80% in 2021, with the full effect arriving in 2022. Naturally, we're also examining discretionary spending across the entire company. As I noted in the prepared remarks, travel expense is an obvious example. Basically, no traveling is happening at all, plus event expenses — and we're reviewing other discretionary spending too, and clearly doing everything we can to offset any possible negative effects.

Speaker

unknown
#68

Thanks.

Speaker

unknown
#69

Mr. Jones has the next question. Please give your name and your company's name, and then ask your question.

Speaker

unknown
#70

Good afternoon, this is Tony Jones from Redburn. I appreciate you taking my questions. There are two remaining that I have. One is for Wolfgang. Could you discuss what the cost synergies amounted to during Q1 and perhaps break them out by business segment, if they were not entirely within Crop Science? I also wanted to revisit the point Liam raised regarding soybeans. The release indicates constant currency sales fell 8%. You mentioned pricing was down in the low single digits. There is also reference to some sales gain in South America. Could you quantify those separate blocks? Would that therefore suggest volumes declined by just under 10%? Thank you.

Speaker

unknown
#71

Okay, I’ll take the first question. I hope you understand that we’d rather not split it out by quarter and by project, given that we have the Fit-to-Win initiative along with the PMI initiative, the platform initiative, and the initiative in Stefan’s business. Please just assume that we are moving this from 30% to 50%. Let me remind you that at the Capital Markets Day, our actual goal was to reach 30% by 2020, so in fact we are ahead of schedule here. All of the initiatives are progressing very well.

Speaker

unknown
#72

Thanks.

Speaker

unknown
#73

Sure, Tony — thanks for those questions. We don’t provide a detailed breakdown, but soybean volumes overall in LatAm did rise, driven by greater Intacta penetration. That said, it’s fairly small relative to the larger picture, so the ballpark figures remain valid. The effect on price is low single digit, and the volume effect you’ll see there will be around the mid-single digit range. Slightly above that.

Speaker

unknown
#74

That's wonderful. I appreciate it.

Speaker

unknown
#75

That's all good.

Speaker

unknown
#76

Our following question is from Mr. Parekh. Kindly give us your name and the company you represent, and then go ahead with your question.

Speaker

unknown
#77

Good afternoon, and thanks for taking my question. This is Keyur Parekh with Goldman Sachs. I have two questions, please. First, during your opening remarks, you indicated that with regard to a litigation settlement, it was hard to envision anything occurring in the near term because of the COVID-19 outbreak. It would be helpful if you could give us some sense of quantification regarding what you meant by near term. Second, Wolfgang, as we consider the possible pushes and pulls on the pension side, it would be helpful to hear your views on what you expect to be paying into the pension plans for this year, given your perspective on discount rate versus asset valuation, and how you think that will differ from what you have done over the last couple of years? Thank you.

Speaker

unknown
#78

Okay, Keyur. I'll begin with the first question you raised about the litigation. Sadly, that's one area where predictive analytics really can't be applied. Giving you any kind of framework for timing considerations is just not possible, and there are two reasons for that. First, as you'd imagine, there's a constant back and forth, I suppose, with the plaintiff side. Second, the substance of those discussions is naturally confidential, and we've committed to strictly honoring our confidentiality obligations, which we keep doing. When I said things have slowed down, what I meant is that meetings aren't happening. Certain lawyers are hard to reach. Really, everything has slowed down quite a bit.

Speaker

unknown
#79

To be fully transparent, we also want you to have the information that matters are not advancing in the manner they would have advanced had the pandemic outbreak not occurred. Conversely, regarding the appeals process, the courts are still operating on essentially an almost normal schedule. Yeah. So everything at that end is fine. Now I'll pass it to Wolfgang for the pensions question. Yeah. So you've seen, for the quarter, a reduction of roughly EUR 700 million in the net pension liability. Two opposing effects were at play there. One is losses on the plan assets. As you can appreciate, the portfolios hold a fair amount of equities. We estimate that this is less for us than for other firms. We also have a pretty good hedge mechanism in there, so the impact from the equity market was somewhat limited. That was about 1.3 billion. On the other side, we had a EUR 2 billion positive effect from increased return expectations, which basically comes from the spreads on bonds and so forth. So that's in Europe, driven not by the base rate but by the spreads.

Speaker

unknown
#80

In the U.S., you saw the same widening of the spread, but clearly the Fed's base rate moves offset that. So you've got two effects pulling in opposite directions. Forecasting for year-end is really tough. Historically, when we did make contributions, they came in at the low 100 millions of euro. But that's history again. We can't predict what's ahead. You surely know that such a payment wouldn't hit our free cash flow, though it would naturally affect Bayer's cash balance.

Speaker

unknown
#81

Thanks.

Speaker

unknown
#82

Michael Leuchten has the next question. Kindly give your name and the firm you represent, then go ahead with what you'd like to ask.

Speaker

unknown
#83

I've just got a single question for Liam. When we consider building up inventory and holding safety stock — and keeping in mind what we went through in Brazil — what options do you have right now to kind of manage the risk of a situation where inventory levels sit high and that ends up hurting pricing as we emerge from COVID-19? Any perspective on that would be useful. Thanks.

Speaker

unknown
#84

Yeah.

Speaker

unknown
#85

Okay, thank you very much, Michael. I believe everyone remembers clearly the problems we had with inventory management in Brazil back in 2017. Because of those problems, many corrective steps were taken — basically making sure there is far greater visibility into the volume of crop protection products that are genuinely sitting in the channel. As you're aware, the channel in Brazil is very long and fragmented. It involves numerous segments and hundreds of separate distributors. The steps we implemented give us very strong visibility into our own inventories and stocks, and let us control them far more tightly than was feasible a few years back. Based on everything we can observe up to this point, channel inventories on our side appear quite healthy in Brazil. We aren't raising any red flags, so there are no significant leftover overhangs from the previous season. Around the middle of the year we'll move into sell-in, when we begin taking more orders and get ready for the new season later in the year. At this moment, though, we aren't seeing any, shall we say, causes for worry. Ultimately, with a strong dollar, those farmers focused on exports are still able to earn solid returns in Brazil.

Speaker

unknown
#86

And receivables look quite solid at the moment, from everything we can see up to now. So I believe we have sufficient mitigation steps in place, and we're watching this very carefully as the broader situation evolves.

Speaker

unknown
#87

Thanks very much, sir.

Speaker

unknown
#88

Our next question is from Mr. Jain. Kindly give us your name and the company you represent, then go ahead with your questions.

Speaker

unknown
#89

Hi, this is Sachin Jain at Bank of America. I have just a couple of questions, please. First, to start off on liquidity: it has come up a few times during the call in different contexts. Werner, you brought it up regarding the glyphosate litigation. Wolfgang, you said it is of paramount importance now, referencing the tough commercial paper and debt market. So I just wanted to check whether there is any Bayer-specific background behind that commentary, or whether it is more just referencing a broader market context. Second, and somewhat related, I wonder if you could remind me of the dividend policy going forward, given the broad market concern around dividends at the moment, and whether there is any link to glyphosate cash out. The reason for the question is that the dividend futures market is pricing quite a substantial cut for next year — not for this year's dividend, for next year. I wonder if you could clarify that. The third question is on revised guidance, and you will provide that as and when you have visibility. Would that be with a quarterly update, or could we think that you may get visibility inter-quarter and require guidance adjustments between quarters and keep?

Speaker

unknown
#90

I think I'll begin with liquidity and the dividend, and then Werner can walk through the guidance outlook once more. On liquidity, a general update that you're seeing as well: broadly speaking, bond markets are available, though with higher new issue premia and wider credit spreads. We are seeing constraints in the commercial paper market, and that's where we fund our short-term cash needs. At our credit level, the market in the U.S. is actually okay-ish, but in Europe it isn't quite open yet. Together with other companies, we're working with the ECB to get that fixed. We're in decent shape, though, since we have bilateral lines in place with some of our relationship banks. As you may recall, we also have a $4.5 billion revolving credit facility, which we don't want to draw. We've also pre-established other facilities, factoring facilities among them. Why do we keep all these safety nets? Because for us, Q2 is always a cash-intensive quarter. We have the dividend, of course, and I'll come to that in a second. We also have our payouts of short-term incentive plans for the company, with some acceleration into Q1. This year, we additionally have an exchange of a bond coming due at the end of the quarter.

Speaker

unknown
#91

We're in fairly good shape. Still, in a crisis such as this, liquidity should be the focus for everyone, and it is for us too. Our dividend policy is unchanged. Tomorrow is our AGM. We've proposed a dividend flat versus the prior year, at EUR 2.80 per share. That rewards last year's good results, both operationally and strategically, including some of the divestitures. Frankly, I also think it matters that some money flows to investors, retail investors especially, given that share prices have fallen quite a bit. Our liquidity planning has accounted for all of this, so there's no reason for us to deviate from what our policy says — namely that we want to provide growing, but at least stable, dividends to our shareholders. Our rule of thumb guideline is 30%-40% of core EPS. Last quarter — last year, sorry — it was more like 44%, but we believe we could justify that because cash inflows came in better than assumed, along with the divestitures. Right now, we do not assume that any potential settlement would affect future dividends. With that, I'll hand it over to you, Werner, on.

Speaker

unknown
#92

Okay, thanks, Wolfgang. Just quickly on the guidance question, Sachin — as both Wolfgang and I said in our prepared remarks, the real problem here is a lack of visibility, and honestly, we also don't have solid grounds on which we could update that guidance. So the way we see it, let's say it will be multiple months before we get to that point, because we're still in the middle of this crisis. The route out of it remains unclear. All we can really describe at this moment are the vectors that matter, and that's what Wolfgang laid out on the call. So you'll have to bear with us on this. We are not looking at any kind of in-quarter guidance update for quarter 2.

Speaker

unknown
#93

Thanks.

Speaker

unknown
#94

Mr. Friedrich has the next question. Kindly give us your name and your firm, then go ahead with what you'd like to ask.

Speaker

unknown
#95

Thanks. This is Falko Friedrichs at Deutsche Bank, and I have two quick questions remaining. First, in Europe the weather seems to have been very dry during April. Do you think that will have an effect on the planting season and on your business? So far, has the weather in the relevant U.S. regions been supportive for planting? Second, could you give an update on the Dicamba litigation and tell us where things currently stand?

Speaker

unknown
#96

Yes. Thanks, Falko. As far as weather goes, we believe our starting position is significantly better than it was a year ago, in both the U.S. and Europe. In the U.S., of course, flooding was the dominant factor last year. This year, I would say the pattern is far more normal. There will still be some swings and roundabouts, but up to now, from a planting standpoint, seasonal preparations have gone well. Provided it stays dry at the right moment, planting should move ahead nicely. At present, we are still working on the assumption of a normal season, a normal U.S. planting season. Of course, that depends heavily on what happens over the next 6 weeks, essentially. For Europe, you will recall that we actually had very heavy rains over the winter, and it has now been dry for quite some time. Rain is forecast again this coming week. As things stand, conditions would still be fine — more in what I would describe as the normal bracket. Hopefully we can steer clear of the drought seen in previous years. Again, only the coming months will show whether or not a drought continues. For us, so far, if I look at orders from both the seeds and the crop protection side, it still currently appears to be a normal season, but what actually goes into the ground and which crop protection products are used depends entirely on the weather we get over the next couple of months.

Speaker

unknown
#97

Things are going well up to this point.

Speaker

unknown
#98

Yeah. Falko, regarding the Dicamba litigation, one of the trials produced a first-instance verdict that we strongly disagree with. It also isn't representative of the Dicamba litigation, since that case involved a peach farmer named Bader. We are entirely opposed to the verdict, because based on our assessment and our perspective it truly isn't substantiated at all. By and large, all of the others involve soybean farmers, and we're talking about roughly 175 farmers consolidated into about 35 cases. We are in discussions with plaintiff lawyers about a possible resolution, but that process is ongoing, so there's no update from those talks at this point in time. Of course, the value is also substantially lower for soybeans, as a one-year crop. For that reason as well, it isn't comparable at all to the first case. Yeah, no read-through there.

Speaker

unknown
#99

All right, thank you so much.

Speaker

unknown
#100

That wraps up our question-and-answer session. Mr. Maier, please go ahead with whatever points you'd like to raise.

Speaker

unknown
#101

Alright, thank you so much, everyone. I truly appreciate the time you've taken along with your feedback and the questions you raised. I hope all of you remain safe and well, and we'll speak again shortly. Thanks.

Speaker

unknown
#102

That wraps up Bayer's conference call with investors and analysts on the first quarter 2020 results, everyone. We appreciate your taking part. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.